Barrett's esophagus

Current Opinion in Gastroenterology

Volumn 13, Issue 4, 1997, Pages 343-348

  Morales, Thomas G ^a   Sampliner, Richard E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; BIOLOGICAL MARKER; TUMOR MARKER;

BARRETT ESOPHAGUS; CANCER RISK; DIGESTIVE TRACT ENDOSCOPY; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; HISTOLOGY; HUMAN; INTESTINE METAPLASIA; SHORT SURVEY;

EID: 0030758574     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199707000-00012     Document Type: Short Survey

References (28)

1. Weinstein WM, Ippoliti AF: The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc 1996, 44:91-96. In this clear, concise review of definitional and diagnostic issues regarding Barrett's esophagus, special emphasis is placed on identification of endoscopic landmarks and the distinction between Barrett's esophagus and intestinal metaplasia of the gastric cardia.
2. Riddell RH: Early detection of neoplasia of the esophagus and gastroesophageal junction. Am J Gastroenterol 1996, 91:853-863. This thorough review of esophageal cancer includes risk factors for Barrett's esophagus and esophageal adenocarcinoma. Other issues covered include dysplasia and endoscopic surveillance.
3. Spechler SJ, Goyal RK: The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 1996, 110:614-621. In this historical review of Barrett's esophagus with a focus on diagnostic challenges, an alternative classification for esophageal intestinal metaplasia is proposed.
4. Canto MIF, Setrakian S, Petras RE, Blades E, Chak A, Sivak M: Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 1996, 44:1-7. Fourteen patients with Barrett's esophagus and 12 control patients underwent endoscopy with methylene blue staining of the esophagus. The overall accuracy of methylene blue staining for intestinal metaplasia was 95%.
5. Sawhney RA, Shields HM, Allan CH, Boch JA, Trier JS, Antonioli DA: Morphological characterization of the squamocolumnar junction of the esophagus in patients with and without Barrett's epithelium. Dig Dis Sci 1996, 41:1088-1098.
6. Navab F, Avunduk C, Gang D, Frankel K: Bulimia nervosa complicated by Barrett's esophagus and esophageal cancer. Gastointest Endosc 1996, 44:492-494.
7. Nishimaki T, Watanabe K, Suzuki T, Hatakeyama K, Watanabe H: Early esophageal adenocarcinoma arising in a short segment of Barrett's mucosa after total gastrectomy. Am J Gastroenterol 1996, 91:1856-1857.
8. Savarino V, Mela GS, Zentilin P, Mele MR, Mansi C, Remagnino AC, Vigneri S, Malesci A, Belicchi M, Lapertosa G, Celle G: Time pattern of gastric acidity in Barrett's esophagus. Dig Dis Sci 1996, 41:1379-1383.
9. Hirschowitz BI: Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci 1996, 41:1384-1391.
10. Poynton AR, Walsh TN, O'Sullivan G, Hennessy TPJ: Carcinoma arising in familial Barrett's esophagus. Am J Gastroenterol 1996, 91: 1855-1856.
11. Weston AP, Krmpotich P, Makdisi WF, Cherian R, Dixon A, McGregor DH, Banerjee SK: Short sement Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. Am J Gastroenterol 1996, 91:981-982. Two hundred thirty-seven patients underwent elective upper endoscopy for clinical indications. Short-segment Barrett's esophagus was suspected in 42 patients and was confirmed by biopsy in 48%. Only 53% of these individuals presented with typical or complicated GERD.
12. Johnston M, Hammond AS, Laskin W, Jones DM: The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol 1996, 91:1507-1511. One hundred seventy patients without Barrett's esophagus were evaluated for intestinal metaplasia of the esophagogastric junction. Although 16 patients had intestinal metplasia, in 12 of these the esophagogastric junction and squamo-columnar junction were at the same level. Pyrosis and regurgitation were more common in those with intestinal metaplasia.
13. Wright TA, Gray MR, Morris AI, Gilmore IT, Ellis A, Smart HL, Myskow M, Nash J, Donnelly RJ, Knigsnorth AN: Cost effectiveness of detecting Barrett's esophagus. Gut 1996, 39:574-579. Six of 166 patients with Barrett's esophagus who underwent surveillance endoscopy developed esophageal cancer. These patients were compared with a group of similar patients who had not undergone surveillance endoscopy. The former group was found to have their cancer identified at a significantly earlier stage.
14. Van der Burgh A, Dees J, Hop WCJ, Van Blankenstein M: Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996, 39:5-8. Eight of 166 patients with Barrett's esophagus who had not undergone surveillance endoscopy developed esophageal adenocarcinoma. Only two of these patients were determined to have died from their esophageal cancer.
15. McDonald ML, Trastek VF, Allen MS, Deschamps C, Pairolero PC: Barrett's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996, 111:1135-1140. One hundred thirteen patients with Barrett's esophagus underwent antireflux procedures. Morbidity related to the surgical procedure occurred in 36%. Of the 72 who had postoperative endoscopy, all had persisting Barrett's esophagus. Three patients developed esophageal adenocarcinoma for an incidence of one in 274 patient-years of follow-up.
16. Komorowski RA, Hogan WJ, Chausow DD: Barrett's ulcer: the clinical significance today. Am J of Gastroenterol 1996, 2310-2313.
17. Panjehpour M, Overholt BF, Vo-Dihn T, Haggitt RC, Edwards DH, Buckley FP: Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology 1996, 111:93-101. Thirty-six patients with Barrett's esophagus underwent endoscopy with laser-induced fluorescence spectroscopy to detect high-grade dysplasia. Ninety-six percent of nondysplastic mucosa was classified as benign, and 90% of high-grade dysplasia samples were identified as premalignant.
18. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Lovine DS, Rabinovitch PS, Reid BJ: 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A 1996, 93:7081-7084.
19. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ: Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996, 13:1867-1873.
20. Zhuang Z, Vortmeyer AO, Mark EJ, Odze R, Emmert-Buck MR, Merino MJ, Moon H, Liotta LA, Duray PH: Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res 1996, 1961-1964.
21. Schneider PM, Casson AG, Levin B, Garewal HS, Hoelscher AH, Becker K, Dittler H-J, Cleary KR, Troster M, Siewert JR, Roth JA: Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study in ninety-eight cases. J Thorac Cardiovasc Surg 1996, 111:323-333. Twenty-three of 50 patients with Barrett's cancer had p53 mutations as opposed to none of 45 with Barrett's esophagus who had either no dysplasia or low-grade dysplasia.
22. Malesci A, Savarino V, Zentilin P, Belicchi M, Mela GS, Lapertosa G, Bocchia P, Ronchi G, Franceschi M: Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996, 44:700-705. Partial regression of the length of Barrett's esophagus is reported with use of omeprazole 60 mg/d. Esophageal acid exposure was normalized in 12 of 14 patients. The antisecretory effect of omeprazole as measured by 24-hour gastric pH monitoring was maintained throughout the year of therapy.
23. Ortiz A, Martinez deHaro LF, Morales PPG, Molina J, Bermejo J, Liron R, Aguilar R: Conservative treatment vs. antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996, 83:274-278.
24. Sampliner RE, Fennerty MB, Garewal HS: Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 1996, 44:523-525. High-dose omeprazole (mean dose, 56 mg/d) to control esophageal pH and endoscopic multipolar electro-coagulation reversed a segment of Barrett's esophagus in 10 patients. The entire Barrett's segment was reversed in five patients at the time of this report. Only 7% of the ambulatory treatment sessions resulted in a complication, one requiring hospitalization.
25. Overholt FB, Panjehpour M: Photodynamic therapy for Barrett's esophagus: clinical update. Am J Gastroenterol 1996, 91:1719-1723. Thirty-six patients with Barrett's esophagus with dysplasia or superficial carcinoma were treated with photodynamic therapy and omeprazole. At the time of this report 10 patients had reversal of Barrett's esophagus and another 19 had Barrett's without dysplasia. Twenty-one patients developed an esophageal stricture.
26. Barr H, Shepherd N, Dix A, Roberts DJH, Tan WC, Krasner N: Eradication of high grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphryin IX. Lancet 1996, 348:584-585.
27. Heitmiller RF, Redmond M, Hamilton SR: Barrett's esophagus with high grade dysplasia: an indication for prophylactic esophagectomy. Ann Surg 1996, 224:66-71. Thirty consecutive patients with Barrett's esophagus with high-grade dysplasia underwent esophagectomy, with 13 having adenocarcinoma in the resected specimen. Eight patients had stage I cancer with seven being alive at a mean follow-up of 18 months. One death and three major complications occurred postoperatively.
28. Edwards MJ, Gable DR, Lentsch AB, Richardson JD: The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high grade dysplasia. Ann Surg 1996, 223:585-591.